Inozyme Pharma's total assets for Q4 2024 were $123.18M, a decrease of -14.08% from the previous quarter. INZY total liabilities were $65.36M for the fiscal quarter, a 7.90% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.